Literature DB >> 32289310

Regular Bleeding Risk Assessment Associated with Reduction in Bleeding Outcomes: The mAFA-II Randomized Trial.

Yutao Guo1, Deirdre A Lane2, Yundai Chen1, Gregory Y H Lip3.   

Abstract

BACKGROUND: The mobile atrial fibrillation application (mAFA-II) randomized trial reported that a holistic management strategy supported by mobile health reduced atrial fibrillation-related adverse outcomes. The present study aimed to assess whether regular reassessment of bleeding risk using the Hypertension, Abnormal renal and liver function, Stroke, Bleeding, Labile international normalized ratio, Elderly, Drugs or alcohol (HAS-BLED) score would improve bleeding outcomes and oral anticoagulant (OAC) uptake.
METHODS: Bleeding risk (HAS-BLED score) was monitored prospectively using mAFA, and calculated as 30 days, days 31-60, days 61-180, and days 181-365. Clinical events and OAC changes in relation to the dynamic monitoring were analyzed.
RESULTS: We studied 1793 patients with atrial fibrillation (mean, standard deviation, age 64 years, 24 years, 32.5% female). Comparing baseline and 12 months, the proportion of atrial fibrillation patients with HAS-BLED ≥3 decreased (11.8% vs 8.5%, P = .008), with changes in use of concomitant nonsteroidal antiinflammatory drugs/antiplatelets, renal dysfunction, and labile international normalized ratio contributing to the decreased proportions of patients with HAS-BLED ≥3 (P < .05). Among 1077 (60%) patients who had 4 bleeding risk assessments, incident bleeding events decreased significantly from days 1-30 to days 181-365 (1.2% to 0.2%, respectively, P < .001). Total OAC usage increased from 63.4% to 70.2% (Ptrend < .001). Compared with atrial fibrillation patients receiving usual care (n = 1136), bleeding events were significantly lower in atrial fibrillation patients with dynamic monitoring of their bleeding risk (mAFA vs usual care, 2.1%, 4.3%, P = .004). OAC use decreased significantly by 25% among AF patients receiving usual care, when comparing baseline to 12 months (P < .001).
CONCLUSION: Dynamic risk monitoring using the HAS-BLED score, together with holistic App-based management using mAFA-II reduced bleeding events, addressed modifiable bleeding risks, and increased uptake of OACs.
Copyright © 2020 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Anticoagulants; Atrial fibrillation; Bleeding; Dynamic risk assessment; HAS-BLED; Mobile health

Year:  2020        PMID: 32289310     DOI: 10.1016/j.amjmed.2020.03.019

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  17 in total

Review 1.  Atrial fibrillation.

Authors:  Bianca J J M Brundel; Xun Ai; Mellanie True Hills; Myrthe F Kuipers; Gregory Y H Lip; Natasja M S de Groot
Journal:  Nat Rev Dis Primers       Date:  2022-04-07       Impact factor: 52.329

2.  Impact of Non-Vitamin K Antagonist Oral Anticoagulants on the Change of Antithrombotic Regimens in Patients with Atrial Fibrillation Undergoing Percutaneous Coronary Intervention.

Authors:  Soonil Kwon; Jin Hyung Jung; Eue Keun Choi; Seung Woo Lee; Jiesuck Park; So Ryoung Lee; Jeehoon Kang; Kyungdo Han; Kyung Woo Park; Seil Oh; Gregory Y H Lip
Journal:  Korean Circ J       Date:  2021-01-25       Impact factor: 3.243

3.  Changes in anticoagulant prescription patterns over time for patients with atrial fibrillation around the world.

Authors:  Monika Kozieł; Christine Teutsch; Valentina Bayer; Shihai Lu; Venkatesh K Gurusamy; Jonathan L Halperin; Kenneth J Rothman; Hans-Christoph Diener; Chang-Sheng Ma; Menno V Huisman; Gregory Y H Lip
Journal:  J Arrhythm       Date:  2021-07-10

4.  Atrial fibrillation.

Authors: 
Journal:  Nat Rev Dis Primers       Date:  2016-03-31       Impact factor: 65.038

5.  Integrated care for optimizing the management of stroke and associated heart disease: a position paper of the European Society of Cardiology Council on Stroke.

Authors:  Gregory Y H Lip; Deirdre A Lane; Radosław Lenarczyk; Giuseppe Boriani; Wolfram Doehner; Laura A Benjamin; Marc Fisher; Deborah Lowe; Ralph L Sacco; Renate Schnabel; Caroline Watkins; George Ntaios; Tatjana Potpara
Journal:  Eur Heart J       Date:  2022-07-07       Impact factor: 35.855

6.  Intracerebral Hemorrhage and Exposure to Antithrombotic Drugs.

Authors:  Peter Brønnum Nielsen; Truman J Milling; Gregory Y H Lip
Journal:  JAMA Netw Open       Date:  2021-05-03

7.  Mobile health technology-supported atrial fibrillation screening and integrated care: A report from the mAFA-II trial Long-term Extension Cohort.

Authors:  Yutao Guo; Jun Guo; Xiangmin Shi; Yuan Yao; Yihong Sun; Yunlong Xia; Bo Yu; Tong Liu; Yundai Chen; Gregory Y H Lip
Journal:  Eur J Intern Med       Date:  2020-10-13       Impact factor: 4.487

8.  Oral Anticoagulants for Nonvalvular Atrial Fibrillation in Patients With High Risk of Gastrointestinal Bleeding.

Authors:  Gregory Y H Lip; Allison V Keshishian; Yan Zhang; Amiee Kang; Amol D Dhamane; Xuemei Luo; Christian Klem; Mauricio Ferri; Jenny Jiang; Huseyin Yuce; Steven Deitelzweig
Journal:  JAMA Netw Open       Date:  2021-08-02

9.  2021 Focused Update Consensus Guidelines of the Asia Pacific Heart Rhythm Society on Stroke Prevention in Atrial Fibrillation: Executive Summary.

Authors:  Tze-Fan Chao; Boyoung Joung; Yoshihide Takahashi; Toon Wei Lim; Eue-Keun Choi; Yi-Hsin Chan; Yutao Guo; Charn Sriratanasathavorn; Seil Oh; Ken Okumura; Gregory Y H Lip
Journal:  Thromb Haemost       Date:  2021-11-13       Impact factor: 5.249

10.  The Effects of Implementing a Mobile Health-Technology Supported Pathway on Atrial Fibrillation-Related Adverse Events Among Patients With Multimorbidity: The mAFA-II Randomized Clinical Trial.

Authors:  Yuan Yao; Yutao Guo; Gregory Y H Lip
Journal:  JAMA Netw Open       Date:  2021-12-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.